psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»10.30629/2618-6667-2019-17-4-74-80psychiatry-429Research ArticleПСИХОПАТОЛОГИЯ, КЛИНИЧЕСКАЯ И БИОЛОГИЧЕСКАЯ ПСИХИАТРИЯPSYCHOPATHOLOGY, CLINICAL AND BIOLOGICAL PSYCHIATRYИзменение соотношения форм белка-предшественника р-амилоида (АРР) в тромбоцитах при шизофрении по сравнению с контрольной группойChange in Ratio of Platelet Beta-Amyloid Precursor Protein (APP) Forms in Schizophrenia Compared with Control GroupТерешкинаЕ. Б.TereshkinaE. B.

Терешкина Елена Борисовна - кандидат биологических наук.

Elena B. Tereshkina - PhD, Cand. of Sci. (Biol.).

tereshkina.el@yandex.ruhttps://orcid.org/0000-0003-1369-8658БокшаИ. С.BokshaI. S.

Бокша Ирина Сергеевна - доктор биологических наук.

Irina S. Boksha - PhD, Dr. of Sci. (Biol.), MHRC; Leading Researcher Scientist, Gamaleya CEM.

Moscow

boksha_irina@mail.ruhttps://orcid.org/0000-0002-3574-2165ПрохороваТ. А.ProkhorovaT. A.

Прохорова Татьяна Андреевна - научный сотрудник.

Tatyana A. Prokhorova – Researcher.

gnidra@mail.ruhttps://orcid.org/0000-0002-5996-6606СавушкинаО. К.SavushkinaO. K.

Савушкина Ольга Константиновна - кандидат биологических наук.

Olga K. Savushkina - PhD, Cand. of Sci. (Biol.).

osavushkina1@yandex.ruhttps://orcid.org/0000-0001-7744-533XБурбаеваГ. Ш.BurbaevaG. Sh.

Бурбаева Гульнур Шингожиевна - доктор биологических наук, профессор, заведующий лабораторией нейрохимии.

Gulnur Sh. Burbaeva - PhD, Dr. of Sci. (Biol.), Professor, Head of the Laboratory of Neurochemistry.

gburb@mail.ruhttps://orcid.org/0000-0002-7847-2716МорозоваМ. А.MorozovaM. A.

Морозова Маргарита Алексеевна - доктор медицинских наук, профессор, руководитель лаборатории психофармакологии.

Margarita A. Morozova - PhD, MD, Dr. of Sci. (Med.), Professor, Head of the Laboratory of Psychopharmacology.

margmorozova@gmail.comМукаетова-ЛадинскаЕ. Б.Mukaetova-LadinskaE. B.

Мукаетова-Ладинска Елизабета - доктор медицинских наук, профессор, заведующая кафедрой Департамента нейронаук, психологии и поведения.

Лестер

Elizabeta Mukaetova-Ladinska - PhD, MD, Dr. of Sci. (Med.), Professor, Chair of the Department of Neuroscience, Psychology and Behavior.

eml12@leicester.ac.ukФГБНУ НЦПЗРоссияFSBSI Mental Health Research CentreRussian FederationФГБНУ НЦПЗ; НИЦ Эпидемиологии и микробиологии имени Н.Ф. ГамалеиРоссияFSBSI Mental Health Research Centre; .F. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health of the Russian FederationRussian FederationУниверситет ЛестераВеликобританияUniversity of LeicesterUnited Kingdom2019270120201747480Copyright © Терешкина Е.Б., Бокша И.С., Прохорова Т.А., Савушкина О.К., Бурбаева Г.Ш., Морозова М.А., Мукаетова-Ладинска Е.Б., 20202020Терешкина Е.Б., Бокша И.С., Прохорова Т.А., Савушкина О.К., Бурбаева Г.Ш., Морозова М.А., Мукаетова-Ладинска Е.Б.Tereshkina E.B., Boksha I.S., Prokhorova T.A., Savushkina O.K., Burbaeva G.S., Morozova M.A., Mukaetova-Ladinska E.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/429Обоснование

Обоснование: белок-предшественник р-амилоида (АРР) и его протеолитические фрагменты выполняют важные физиологические функции в нервной системе. Данные литературы свидетельствуют о том, что метаболизм АРР при шизофрении может быть нарушен.

Цель исследования

Цель исследования: сравнение концентрации различных форм АРР в тромбоцитах крови больных шизофренией и в контрольной группе.

Материал и методы

Материал и методы: исследованы тромбоциты больных параноидной шизофренией (F20.0; n = 14; возраст 19-35 лет) и контрольной группы (n = 14; возраст 20-36 лет). Взятие крови у больных проводилось до начала курса антипсихотической терапии. Для оценки концентрации форм АРР был использован метод иммуноблоттинга с хемилюминесцентным усилением сигнала (ECL). Оценивали интенсивность засветки зон, соответствующих 130 кДа (зона 1), 110 кДа (зона 2) и 100 кДа (зона 3), а также рассчитывали отношение интенсивностей: {зона 1/(зоны 2 + 3)}.

Результаты

Результаты: в группе больных шизофренией интенсивность засветки зоны 1 достоверно снижена относительно контроля (р = 0,0001), ее доля составляет 9,7% всех детектируемых форм АРР (против 29,2% в контроле). Отношение интенсивности засветки зоны 1 к суммарной интенсивности засветки зоны 2 и 3 {зона 1/(зоны 2 + 3)} также достоверно снижено по сравнению с контролем (р = 0,00003). У больных наблюдались достоверные обратные корреляции интенсивности засветки зоны 1, зоны 2 и отношения {зона 1/(зоны 2 + 3)} с возрастом: R = -0,68, р = 0,007, R = -0,77, р = 0,001, R = -0,55, р = 0,04 соответственно, но эти связи отсутствовали в группе контроля. Обнаружена отрицательная корреляция отношения интенсивности засветки {зона 1/(зоны 2 + 3)} с баллами по «подшкале» PANSS общей психопатологии (PANSSpsy): R = -0,57, р = 0,035.

Заключение

Заключение: в тромбоцитах больных шизофренией снижено количество отдельных форм APP и изменено их соотношение. Учитывая регуляторную активность фрагментов АРР в нервной системе и обнаруженные изменения метаболизма АРР, необходимо проведение дальнейших исследований по изучению роли АРР при шизофрении.

Background

Background: p-amyloid precursor protein (APP) and its proteolytic fragments have important physiological functions in nervous system. Literature data suggests that APP metabolism may be impaired in schizophrenia. Aim of study: to compare concentration of platelet APP forms in patients with schizophrenia and in control group.

Material and methods

Material and methods: 14 patients (19-35 years old) with acute paranoid schizophrenia (ICD-10 F20.0) and 14 normal controls (20-36 years old) were included to analyse concentration of platelet APP forms by ECL-immunoblotting. Blood was collected before starting antipsychotic therapy. Net intensity was measured for zones corresponding to 130 kDa (zone 1), 110 kDa (zone 2) and 100 kDa (zone 3), and {zone 1/(zone 2 + zone 3)} ratio was calculated.

Results

Results: intensity of zone 1 was significantly reduced in patients compared with controls (р = 0,0001), its proportion comprised 9,7% of all detected APP forms (vs 29,2% in controls). {zone 1/(zone 2 + zone 3)} ratio was also reduced in patients compared with controls (р = 0,00003). Significant negative correlations of zone 1, zone 2, and {zone 1/(zone 2 + zone 3)} with age were present in patients: R = -0,68, р = 0,007, R = -0,77, р = 0,001, R = -0,55, р = 0,04, respectively, but these links were absent in control group. Negative correlation between {zone 1/(zone 2 + zone 3)} and PANSSpsy score was found in patients: R = -0,57, р = 0,035.

Conclusion

Conclusion: concentration of distinct APP forms in platelets of patients with schizophrenia and their ratio are altered. Considering the regulatory activity of APP fragments in nervous system and revealed changes in APP metabolism, further research is needed on APP role in schizophrenia.

белок-предшественник р-амилоидатромбоцитышизофренияp-amyloid precursor proteinplateletsschizophreniaReferences. van der Kant R, Goldstein LS. Cellular functions of the amyloid precursor protein from development to dementia. Dev Cell. 2015;32(4):502-515. https://doi:10.1016/j.devcel.2015.01.022. van der Kant R, Goldstein LS. Cellular functions of the amyloid precursor protein from development to dementia. Dev Cell. 2015;32(4):502-515. https://doi:10.1016/j.devcel.2015.01.022Coronel R, Bernabeu-Zornoza A, Palmer C, et al. Role of аmyloid precursor protein (APP) and its derivatives in the biology and cell fate specification of neural stem cells. Molecular Neurobiology. 2018;55(9):7107—7117. https://doi:10.1007/s12035-018-0914-2Coronel R, Bernabeu-Zornoza A, Palmer C, et al. Role of аmyloid precursor protein (APP) and its derivatives in the biology and cell fate specification of neural stem cells. Molecular Neurobiology. 2018;55(9):7107—7117. https://doi:10.1007/s12035-018-0914-2Hefter D, Draguhn A. APP as a Protective Factor in Acute Neuronal Insults. Front Mot. Neurosci. 2017;10:1-16. https://doi:10.3389/fnmol.2017.00022.Hefter D, Draguhn A. APP as a Protective Factor in Acute Neuronal Insults. Front Mot. Neurosci. 2017;10:1-16. https://doi:10.3389/fnmol.2017.00022.Religa D, Laudon H, Styczynska M, et al. Amyloid p Pathology in Alzheimer's Disease and Schizophrenia. Am. J. Psychiatry. 2003;160:867-872. https://doi:10.1176/appi.ajp.160.5.867.Religa D, Laudon H, Styczynska M, et al. Amyloid p Pathology in Alzheimer's Disease and Schizophrenia. Am. J. Psychiatry. 2003;160:867-872. https://doi:10.1176/appi.ajp.160.5.867.Frisoni GB, Prestia A, Geroldi C, et al. Alzheimer's CSF markers in older schizophrenia patients. Int. J. Geriatr. Psychiatry. 2011;26(6):640-648. https://doi:10.1002/gps.2575.Frisoni GB, Prestia A, Geroldi C, et al. Alzheimer's CSF markers in older schizophrenia patients. Int. J. Geriatr. Psychiatry. 2011;26(6):640-648. https://doi:10.1002/gps.2575.Albertini V, Benussi L, Paterlini A, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. Electrophoresis. 2012;33(24):3738-3744. https://doi:10.1002/elps.2012003075.Albertini V, Benussi L, Paterlini A, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. Electrophoresis. 2012;33(24):3738-3744. https://doi:10.1002/elps.2012003075.Bush AI, Martins RN, Rumble B, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. Biol. Chem. 1990;265(26):15977-15983.Bush AI, Martins RN, Rumble B, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. Biol. Chem. 1990;265(26):15977-15983.Savonenko AV, Melnikova T, Laird FM, et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Nat. Acad. Sci. USA. 2008;105(14):5585-5590. https://doi:10.1073/pnas.0710373105.Savonenko AV, Melnikova T, Laird FM, et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Nat. Acad. Sci. USA. 2008;105(14):5585-5590. https://doi:10.1073/pnas.0710373105.Kamikubo Y, Takasugi N, Niisato K, et al. Consecutive Analysis of BACE1 Function on Developing and Developed Neuronal Cells. J. Alzheimers Dis. 2017;56(2):641-653. https://doi:10.3233/JAD-160806.Kamikubo Y, Takasugi N, Niisato K, et al. Consecutive Analysis of BACE1 Function on Developing and Developed Neuronal Cells. J. Alzheimers Dis. 2017;56(2):641-653. https://doi:10.3233/JAD-160806.Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J. Neurol. Sci. 2006;240(1-2):53-58. https//:doi:10.1016/j.jns.2005.09.002.Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J. Neurol. Sci. 2006;240(1-2):53-58. https//:doi:10.1016/j.jns.2005.09.002.Evin G, Li Q-X. Platelets and Alzheimer's disease: Potential of APP as a biomarker. World J. Psychi-atr. 2012;2(6):102-113. https://doi:10.5498/wjp.v2.i6.102.Evin G, Li Q-X. Platelets and Alzheimer's disease: Potential of APP as a biomarker. World J. Psychi-atr. 2012;2(6):102-113. https://doi:10.5498/wjp.v2.i6.102.Colciaghi F, Marcello E, Borroni B, et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology. 2004;62(3):498-501. https://doi:10.1212/01.WNL.0000106953.49802.9C.Colciaghi F, Marcello E, Borroni B, et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology. 2004;62(3):498-501. https://doi:10.1212/01.WNL.0000106953.49802.9C.Sokol DK, Chen D, Farlow MR, et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J. Child Neurol. 2006;21(6):444-449. https://doi:10.1177/08830738060210062201.Sokol DK, Chen D, Farlow MR, et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J. Child Neurol. 2006;21(6):444-449. https://doi:10.1177/08830738060210062201.Wang H, Xu H, Wang X, et al. Amyloid precursor protein associates with autism spectrum disorder: a potential candidate biomarker for early screening. Int. J. Clin. Exp. Med. 2016;9(11):22259-22266. www.ijcem.com/ISSN:1940-5901/IJCEM0020275.Wang H, Xu H, Wang X, et al. Amyloid precursor protein associates with autism spectrum disorder: a potential candidate biomarker for early screening. Int. J. Clin. Exp. Med. 2016;9(11):22259-22266. www.ijcem.com/ISSN:1940-5901/IJCEM0020275.Chung JK, Nakajima S, Plitman E, et al. p-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. Am. J. Geriatr. Psychiatry. 2016;24(10):923-939. https//:doi:10.1016/j.jagp.2016.03.013.Chung JK, Nakajima S, Plitman E, et al. p-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review. Am. J. Geriatr. Psychiatry. 2016;24(10):923-939. https//:doi:10.1016/j.jagp.2016.03.013.Wegiel J, Frackowiak J, Mazur-Kolecka B, et al. Abnormal intracellular accumulation and extracellular Ap deposition in idiopathic and Dup15q11.2-q13 autism spectrum disorders. PLoS One. 2012;7(5):e35414. https://doi:10.1371/journal.pone.0035414.Wegiel J, Frackowiak J, Mazur-Kolecka B, et al. Abnormal intracellular accumulation and extracellular Ap deposition in idiopathic and Dup15q11.2-q13 autism spectrum disorders. PLoS One. 2012;7(5):e35414. https://doi:10.1371/journal.pone.0035414.Burbaeva GSh, Boksha IS, Tereshkina EB, et al. Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia. World J. Biol. Psychiatry. 2006;7(2):75-81. https://doi:10.1080/15622970510029957.Burbaeva GSh, Boksha IS, Tereshkina EB, et al. Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia. World J. Biol. Psychiatry. 2006;7(2):75-81. https://doi:10.1080/15622970510029957.Boksha IS, Savushkina OK, Tereshkina EB, et al. Enzymes of Glutamate System. In: Biochemical Approaches for Glutamatergic Neurotransmission. Neuromethods. Springer Protocols. Parrot, Sandrine, Denoroy, Luc (Eds.). 2018:469-506. https://doi: 10.1007/978-1-4939-7228-9.Boksha IS, Savushkina OK, Tereshkina EB, et al. Enzymes of Glutamate System. In: Biochemical Approaches for Glutamatergic Neurotransmission. Neuromethods. Springer Protocols. Parrot, Sandrine, Denoroy, Luc (Eds.). 2018:469-506. https://doi: 10.1007/978-1-4939-7228-9.Davies TA, Long HJ, Sgro K, et al. Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Neurobiol. Aging. 1997;18(2):147-153. PMID:258891.Davies TA, Long HJ, Sgro K, et al. Activated Alzheimer disease platelets retain more beta amyloid precursor protein. Neurobiol. Aging. 1997;18(2):147-153. PMID:258891.Prodan CI, Ross ED, Stoner JA, et al. Coatedplatelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76(3):247-252. https://doi:10.1212/WNL.0b013e3182074bd2.Prodan CI, Ross ED, Stoner JA, et al. Coatedplatelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76(3):247-252. https://doi:10.1212/WNL.0b013e3182074bd2.Jelic V, Hagman G, Yamamoto NG, et al. Abnormal platelet amyloid-p protein precursor (ApPP) metabolism in Alzheimer's disease: identification and characterization of a new ApPP isoform as potential biomarker. J. Alzheimers Dis. 2013;35(2):285-295. https://doi:10.3233/JAD-122122.Jelic V, Hagman G, Yamamoto NG, et al. Abnormal platelet amyloid-p protein precursor (ApPP) metabolism in Alzheimer's disease: identification and characterization of a new ApPP isoform as potential biomarker. J. Alzheimers Dis. 2013;35(2):285-295. https://doi:10.3233/JAD-122122.Zainaghi IA, Talib LL, Diniz BS, et al. Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. J. Neural. Transm. (Vienna). 2012;119(7):815-819. https://doi:10.1007/s00702-012-0807-x.Zainaghi IA, Talib LL, Diniz BS, et al. Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease. J. Neural. Transm. (Vienna). 2012;119(7):815-819. https://doi:10.1007/s00702-012-0807-x.Borroni B, Agosti C, Marcello E, et al. Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp. Gerontol. 2010;45(1):53-56. https://doi:10.1016/j.exger.2009.08.004.Borroni B, Agosti C, Marcello E, et al. Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp. Gerontol. 2010;45(1):53-56. https://doi:10.1016/j.exger.2009.08.004.

The authors declare that there are no conflicts of interest present.